Sartorius Stedim Biotech Maintains FY26 Guidance Following Q1 Growth

Sartorius Stedim Biotech SA (SDMHF) has posted growth in both net profit and sales revenue for the first quarter of 2026, signaling steady demand within the biopharmaceutical manufacturing sector. The results highlight the company's reliance on its recurring consumables business, which continues to offset headwinds stemming from product mix and tariff impacts. CEO René Fáber expressed confidence in the firm's trajectory, noting that the first quarter aligned with internal expectations. Management anticipates that the second half of the year will outperform the first six months in absolute terms, supporting the company's long-term growth strategy. Financial performance for the quarter showed net profit after non-controlling interest rising 3% to 88.1 million euros, up from 85.6 million euros in the prior-year period. Earnings per share improved to 0.91 euro. Sales revenue reached 761.5 million euros, a 2.3% increase, though growth was significantly higher at 7.9% when measured in constant currencies. Underlying EBITDA grew 1.9% to 233.4 million euros, while the corresponding margin stood at 30.7%, a slight dip from 30.8% last year. The company attributed this development primarily to the strong recurring business with consumables for biopharma manufacturing. Looking toward the remainder of fiscal 2026, Sartorius Stedim Biotech expects constant currency revenue growth between 6% and 10%. This forecast includes a projected 1 percentage point contribution from US tariff surcharges. The company also expects the underlying EBITDA margin to expand to slightly above 31%, driven by volume and scale effects.